Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Hold the line on ARCH

<< Previous

Bullboard Posts

Next >>

Comment by GoldenArmon Dec 03, 2021 3:58pm

85 Views

Post# 34196579

RE:RE:Hold the line on ARCH

We all have issues. Determine what you are willing to risk and live with your decisions. We all have winners and losers. I stopped playing the trading game a long time ago and I do research and find excellent companies to invest in and when I've made what I thing I will get out if it I sell. I haven't even though about selling a single share of ARCH (I think they are well connected and will be worth 4 times what they are worth now). GTLA

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price